Print

Pediatric Asthma Programs With CyDex, Inc. Captisol Technology Acquired by AstraZeneca PLC (AZN)  
10/3/2007 8:52:08 AM

LENEXA, Kan.--(BUSINESS WIRE)--CyDex, Inc. today announced that rights to pediatric asthma development programs that include CyDex’s Captisol-Enabled® technology have been acquired from Verus Pharmaceuticals, Inc. by AstraZeneca.
//-->